Vincent Cottin mainly investigates Internal medicine, Idiopathic pulmonary fibrosis, Surgery, Pathology and Interstitial lung disease. Internal medicine and Gastroenterology are frequently intertwined in his study. His Idiopathic pulmonary fibrosis research is multidisciplinary, incorporating perspectives in Exacerbation, Adverse effect, Etiology and Intensive care medicine.
His biological study spans a wide range of topics, including Clinical trial, Bosentan, Sildenafil, Pharmacotherapy and Radiology. He works mostly in the field of Pathology, limiting it down to concerns involving Lung and, occasionally, Retrospective cohort study. His Interstitial lung disease study combines topics in areas such as Autoantibody, Guideline, Connective tissue disease and Rheumatoid arthritis.
Vincent Cottin mainly focuses on Internal medicine, Idiopathic pulmonary fibrosis, Pathology, Interstitial lung disease and Gastroenterology. His work in the fields of FEV1/FVC ratio, Nintedanib and Pulmonary hypertension overlaps with other areas such as In patient. He studied FEV1/FVC ratio and Placebo that intersect with Clinical endpoint and Adverse effect.
His work deals with themes such as Vascular resistance, Pulmonary function testing and Combined pulmonary fibrosis and emphysema, which intersect with Pulmonary hypertension. The Idiopathic pulmonary fibrosis study combines topics in areas such as Pulmonary fibrosis, Clinical trial, Surgery and Intensive care medicine. He combines subjects such as Idiopathic interstitial pneumonia and Lung with his study of Pathology.
His primary areas of study are Internal medicine, Idiopathic pulmonary fibrosis, FEV1/FVC ratio, In patient and Interstitial lung disease. Vincent Cottin has included themes like Gastroenterology and Cardiology in his Internal medicine study. He interconnects Diffusing capacity and Combined pulmonary fibrosis and emphysema in the investigation of issues within Cardiology.
His research in Idiopathic pulmonary fibrosis intersects with topics in Pulmonologists, Intensive care medicine and Pulmonary fibrosis. The various areas that he examines in his FEV1/FVC ratio study include Respiratory function and Placebo. His Interstitial lung disease research is multidisciplinary, relying on both Fibrosis, Epidemiology, Pathology and Cause of death.
The scientist’s investigation covers issues in Internal medicine, FEV1/FVC ratio, Interstitial lung disease, Idiopathic pulmonary fibrosis and Vital capacity. His Internal medicine study frequently links to other fields, such as Gastroenterology. His work carried out in the field of FEV1/FVC ratio brings together such families of science as Spirometry, Placebo, Nintedanib and Pirfenidone.
The study incorporates disciplines such as Fibrosis, Diffusing capacity, Disease and Hemodynamics in addition to Interstitial lung disease. His Idiopathic pulmonary fibrosis research is within the category of Lung. His Vital capacity research focuses on DLCO and how it relates to Lung volumes, Birt–Hogg–Dubé syndrome, Folliculin, Pneumothorax and Respiratory function.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis
Luca Richeldi;Roland M. du Bois;Ganesh Raghu;Arata Azuma.
The New England Journal of Medicine (2014)
An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias
William D. Travis;Ulrich Costabel;David M. Hansell;Talmadge E. King.
American Journal of Respiratory and Critical Care Medicine (2013)
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.
Ganesh Raghu;Martine Remy-Jardin;Jeffrey L. Myers;Luca Richeldi.
American Journal of Respiratory and Critical Care Medicine (2018)
Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era
Marc Humbert;Olivier Sitbon;Ari Chaouat;Michèle Bertocchi.
International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia
M E Faughnan;V A Palda;G Garcia-Tsao;U W Geisthoff.
Journal of Medical Genetics (2011)
Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity
V. Cottin;H. Nunes;P. Delaval;G. Devouassoux.
European Respiratory Journal (2005)
Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report
Collard Hr;Ryerson Cj;Corte Tj;Jenkins G.
American Journal of Respiratory and Critical Care Medicine (2016)
An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features
Aryeh Fischer;Katerina M. Antoniou;Kevin K. Brown;Jacques Cadranel.
European Respiratory Journal (2015)
Pulmonary hypertension due to left heart diseases.
Jean-Luc Vachiery;Yochai Adir;Joan Albert Barberà;Hunter C. Champion.
Journal of the American College of Cardiology (2013)
Pulmonary hypertension in chronic lung diseases
Werner Seeger;Werner Seeger;Yochai Adir;Joan Albert Barberà;Hunter Champion.
Journal of the American College of Cardiology (2013)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: